Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17298001 | 0.86 | GRIN1 (0.60) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL10967519 | 0.83 | HTT (0.47) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL19104687 | 0.82 | RXFP1 (0.54) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL21457876 | 0.81 | PKM (0.56) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL13833739 | 0.78 | HTT (0.56) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL3462158 | 0.74 | CXCR2 (0.59) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL30433382 | 0.74 | RXFP1 (0.47) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL974164 | 0.74 | HTT (0.48) | RXFP1PKMGRIN1GRIN2AHTT | |
| SCHEMBL18155082 | 0.73 | KDM4E (0.44) | RXFP1GRIN1GRIN2AHTTKDM4E | |
| SCHEMBL12571765 | 0.73 | ALDH1A1 (0.48) | RXFP1PKMGRIN1GRIN2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| WO-2015184011-A2 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-03 | — | — | WO | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2445898-A2 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | RXFP1 129/4885PKM 4145/4885GRIN1 821/4885 |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | RXFP1 189/4885PKM 1694/4885GRIN1 285/4885 |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | RXFP1 129/4885PKM 4145/4885GRIN1 821/4885 |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | RXFP1 129/4885PKM 4145/4885GRIN1 821/4885 |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | RXFP1 4748/4885PKM 3204/4885GRIN1 2955/4885 |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | RXFP1 129/4885PKM 4145/4885GRIN1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.